Clinical Trials Logo

Advanced or Metastatic Melanoma clinical trials

View clinical trials related to Advanced or Metastatic Melanoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT03684785 Terminated - Clinical trials for Advanced or Metastatic Solid Tumors

Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors

Start date: December 13, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1b/2, open-label, two-part, multicenter trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of intratumoral cavrotolimod injections alone and in combination with intravenous pembrolizumab or cemiplimab in patients with Merkel Cell Carcinoma, cutaneous squamous cell carcinoma, and advanced solid tumors. Phase 1b of this trial is a 3+3 dose escalation study evaluating escalating or intermediate dose levels of cavrotolimod given with a fixed dose of pembrolizumab. The Phase 2 dose expansion part of the study will consist of two primary cohorts of patients: Merkel cell carcinoma and cutaneous squamous cell carcinoma. Patients in the Merkel Cell Carcinoma cohort will receive IT cavrotolimod combined with a fixed, standard dose of pembrolizumab while the Cutaneous Squamous Cell Carcinoma cohort will receive IT cavrotolimod combined with a fixed, standard dose of cemiplimab. The Phase 2 dose expansion is designed to provide a preliminary estimate of efficacy in patients that have progressed on an anti-PD-(L)1 CPI.

NCT ID: NCT03673332 Recruiting - Clinical trials for Advanced or Metastatic NSCLC

Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies

EPITOP-01
Start date: August 9, 2019
Phase: Phase 4
Study type: Interventional

The co-primary objectives will be to assess the safety and quality of life under treatment.

NCT ID: NCT01783938 Completed - Clinical trials for Advanced or Metastatic Melanoma

Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)

Start date: April 30, 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of a sequential combination therapy of Nivolumab and Ipilimumab